Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Accelrys Discussing Productivity Gap

By Drug Discovery Trends Editor | April 17, 2012

Accelrys Inc., a leading scientific enterprise R&D software and services company, issued an industry-wide call to close the productivity gap from innovation through commercialization that is slowing product development and time-to-market and hampering competitiveness for science-driven organizations.

Currently, only 25% of projects in industries ranging from pharmaceuticals to aerospace result in the commercialization of new products, according to IDC Manufacturing Insights. Of the 25% of products that make it to market, 66% fail to meet original design or consumer expectations.

“There is growing consensus that new product development is increasingly ineffective – especially for science-driven innovation,” said Joe Barkai, research vice president, product lifecycles strategies at IDC Manufacturing Insights. “Scientific-driven research and development organizations are at a critical juncture – their homegrown systems no longer meet the demands of today’s fastest-to-market environment. They need to be managing the innovation cycle in a new way, and with the same rigor that they have managed their commercialization processes.”

To accelerate innovation and profitability across industries, Accelrys is challenging science-driven organizations to focus on closing the productivity gap from innovation through commercialization. Accelrys also is introducing a scientifically aware enterprise platform as a component of a broader strategy to facilitate a new approach to effectively managing scientific innovation.

For science-driven organizations – particularly those developing products based on modeling at the atomic or molecular level – there is a productivity gap that spans the entire innovation-to-commercialization cycle. This productivity gap exists because traditional information technology solutions have proved incapable of adequately managing the complexity of scientific data and processes and the volumes of unstructured data characteristic of scientific R&D. Scientific processes, for example, are difficult to automate and track, and therefore information is hard to access and reuse during the scientific and product innovation and commercialization cycles. Critical scientific insights and context from the discovery and development stages are never transferred to the commercialization operations of a business because downstream enterprise software cannot handle the unstructured data generated in the R&D cycle. Key parts of the innovation process are consequently lost, along with actionable insights that could bring novel products to market more quickly and cost effectively.

As a result of this productivity gap, innovation is slowing. Manual data collection creates costly bottlenecks requiring repetition and processes that can fail to comply with regulatory standards – potentially leading to rework or even product recalls, slowing time-to-market and threatening product quality. The productivity gap also hinders the ability of science-driven organizations to respond to industry trends such as outsourcing and globalization.

“The challenge for science-driven organizations is the large number of creative cycles required to develop and commercialize great innovations.” says Mike Burkett, Research Vice President at Gartner, Inc. “Bottlenecks that slow down or reduce these cycles result in product of lesser quality or that’s late to market. Industries that have automated and integrated product and manufacturing process development have seen time-to-market improvements. Many science-driven industries remain in the early stages of adopting the same successful practices.”

To learn more about the scientific innovation gap, visit the micro-site and download the IDC Manufacturing Insights whitepaper, “Accelerating Science-Led Innovation for Competitive Advantage,” sponsored by Accelrys. Join the discussion on scientific innovation lifecycle management by registering for the webinar on May 17 at 9 AM PST. This webinar will be hosted by Accelrys with Joe Barkai of IDC Manufacturing Insights as the featured speaker.

Accelrys is introducing the Accelrys Enterprise Platform to support industry efforts toward closing the innovation productivity gap. The Accelrys Enterprise Platform offers the first scientifically aware, service-oriented architecture (SOA) that enables the integration and deployment of broad scientific solutions spanning data management and informatics, enterprise lab management, modeling and simulation, and workflow automation.

“Effective, efficient, end-to-end innovation is critical to the competitiveness of science-driven organizations,” said Accelrys President and Chief Executive Officer Max Carnecchia. “Accelrys is committed to working closely with our customers and partners to close the innovation productivity gap. The Accelrys Enterprise Platform is a game-changer for organizations looking to deliver more competitive products, sooner and more cost-effectively to market.”

The Accelrys Enterprise Platform leverages the company’s deep domain expertise in chemistry, biology and materials science, informatics, predictive science and electronic laboratory management, which includes late-stage laboratory execution for regulated industries. The platform can manage structured and unstructured information encountered early in the innovation cycle, as well as highly structured, automated batch records required by lock-down production. Most importantly, the platform integrates with existing IT infrastructures, including downstream enterprise resource planning (ERP) and product lifecycle management (PLM) systems. The platform’s ability to integrate with existing infrastructure, as well as handle both structured and unstructured scientific data, allows science-driven businesses to gain efficiencies from their legacy systems, reduce complexity and improve productivity from innovation through commercialization.

Date: April 17, 2012
Source: Accelrys Inc.


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE